THE PROJECT AIMS TO DEVELOP AN INNOVATIVE TECHNOLOGY FOR THE DEVELOPMENT OF PERSONALISED, REDUCED TOXIC CHEMOTHERAPY, USING OVARIAN AS A MODEL, BUT WITH THE POSSIBLE EXTENSION OF CANCER TO OTHER TYPES OF CANCER. IN PARTICULAR, IT IS EXPECTED THAT A FULLY AUTOMATED SYSTEM WILL BE DEVELOPED FOR UPTAKE OF PROFICIENCY TESTS TO BE PERFORMED ON PERITONEAL DAMS CELLS FROM PATIENTS IN ORDER TO ASSESS THE INDIVIDUAL RESPONSE TO